Pharmasyntez makes first shipment of cancer medicines to Dominican Republic
ST. PETERSBURG. Sept 19 (Interfax) - The Pharmasyntez Group of Companies has sent its first shipment of antitumor drugs for the treatment of breast and prostate cancer to the Dominican Republic, the company's press service reports.
The manufacturer was Pharmasyntez-Nord.
"Pharmasyntez is the first exporter of Russian anticancer drugs to the republic, so we plan to occupy a worthy niche in this segment and continue our long-term fruitful cooperation," Nikita Punia, executive director of the group of companies, said in the press release.
The group's production facility is located in the St. Petersburg Special Economic Zone.
The first stage of the Pharmasyntez-Nord plant opened in 2017, and the second in the spring of 2023. Construction of the third stage of the complex is planned, with launch scheduled for 2026. As part of the St. Petersburg Internal Economic Forum-2023, Vice-Governor of St. Petersburg Alexey Korabelnikov and General Director of Pharmasyntez-Nord Mikhail Kvasnikov signed an agreement on the construction of the fourth stage. Total investment in the four stages is estimated at nearly 20 billion rubles, of which 9 billion have already been spent.
The company develops and produces drugs in the form of solid dosage forms, lyophilic powders and concentrated solutions. The annual capacity is 10 million vials of liquid and sterile forms, 4 million syringes, 2.5 million lyophilisates and 100 million tablets. Finished goods are exported to the CIS countries.
The Pharmasyntez Group is a large Russian manufacturer of anti-tuberculosis, anti-tumor, anti-retroviral drugs and hospital antibiotics. The company's facilities are located in Irkutsk, Bratsk, Ussuriysk, St. Petersburg, and Tyumen.